Radiofrequency Ablation of Pancreatic Neuroendocrine Tumor

Česká verzia

Authors: J. Hlavsa ¹; V. Procházka ¹ ; Z. Kala ¹; M. Man ²; T. Andrašina ³ ; M. Číhalová ⁴; V. Válek ⁴; M. Crha ⁵; I. Svobodová ⁶; L. Urbanová ⁵
Authors place of work: Chirurgická klinika, LF MU a FN Brno-Bohunice ¹; Chirurgické oddělení Nemocnice TGM, Hodonín ²; Radiologická klinika, LF MU a FN Brno-Bohunice ³; Ústav patologie, LF MU a FN Brno-Bohunice5 Klinika chirurgie malých zvířat, VFU Brno6 Ústav patologie FN u sv. Anny, Brno ⁴
Published in the journal: Klin Onkol 2011; 24(3): 209-215
Category: Case Reports

Summary

Backrounds:
Pancreatic neuroendocrine tumors (PNETs) include a broad range of neoplasms spanning from relatively benign to malignant. Radical resection has been advocated as the only curative method. Debulking (R2) resection can be indicated for locally unresectable PNETs. Debulking surgery improves the quality of life and prolongs overall survival. The disadvantages of this approach include bleeding, pancreatic fistula and tumor spread. No alternative method that would eliminate these complications has been published yet. Considering the encouraging results of the studies describing radiofrequency ablation (RFA) of locally advanced pancreatic cancer, a question arises, whether it might be possible to use RFA as a R2 resection alternative in PNETs.

Case:
A 73-year-old gentleman had been admitted due to abdominal pain and hyperglycaemic syndrome. Contrast-enhanced CT showed a tumor of pancreatic head invading portal vein (PV) and superior mesenteric vein (VMS). A surgery was indicated on the basis of EUS-guided FNAB that verified a PNET of uncertain biological behaviour. The surgery confirmed a locally advanced tumor of pancreatic head invading the PV and SMV. Due to the polymorbidity, radical pancreatoduodenectomy with SMV resection was not indicated. Because of the presence of symptoms, RFA of the PNET using ValleyLab generator with cooltip cluster electrode, was performed. Postoperative course was uneventful. Final immunohistochemical examination verified a well-differentiated grade 1 PNET. The patient was regularly monitored during a three-year follow-up. The quality of life was evaluated using standardized EORT QLQ-30 questionnaire. Pain was assessed by a ten-point visual analogue scale (VAS). Ablated area was evaluated annually by contrast-enhanced CT. Postoperatively, abdominal pain ceased (pain decrease from 2 to 0 on VAS). Insulin dose was reduced from 46 IU (international units) to 20 IU of Humulin-R per day. CT verified tumor regression according to RECIST (response evaluation criteria in solid tumors). During the three-year follow-up, no local progression or tumor dissemination was observed.

Conclusion:
We present the first case report of a patient with locally advanced symptomatic pancreatic neuroendocrine tumor successfully treated by intraoperative radiofrequency ablation. More clinical studies are needed to evaluate the clinical relevance of this cytoreductive method in the PNET indication.

Key words

pancreas – neuroendocrine tumor - radiofrequency ablation – debulking resection

This work was supported by grants of IGA of the Ministry of Health NS10419-3/2009 and NS10239-3/2009.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. Phan GQ, Yeo CJ, Hruban RH et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998; 2(5): 472–482.

2. Jordan PH Jr. A personal experience with pancreatic and duodenal neuroendocrine tumors. J Am Coll Surg 1999; 189(5): 470–482.

3. Dralle H, Krohn SL, Karges W et al. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 2004; 28(12): 1248–1260.

4. Dial PF, Braasch JW, Rossi RL et al. Management of nonfunctioning islet cell tumors of the pancreas. Surg Clin North Am 1985; 65(2): 291–299.

5. Madura JA, Cummings OW, Wiebke EA et al. Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg 1997; 63(7): 573–577.

6. Bartsch DK, Schilling T, Ramaswamy A et al. Management of nonfunctioning islet cell carcinomas. World J Surg 2000; 24(11): 1418–1424.

7. Matthews BD, Heniford BT, Reardon PR et al. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas. Am Surg 2000; 66(12): 1116–1122.

8. Falconi M, Bettini R, Boninsegna L et al. Surgical strategy in the treatment of pancreatic neuroendocrine tumors. JOP 2006; 7(1): 150–156.

9. Norton JA, Sugarbaker PH, Doppman JL et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986; 203(4): 352–359.

10. McEntee GP, Nagorney DM, Kvols LK et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108(6): 1091–1096.

11. Danforth DN Jr, Gorden P, Brennan MF. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 1984; 96(6): 1027–1037.

12. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112(6): 1024–1031.

13. Chamberlain RS, Canes D, Brown KT et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190(4): 432–445.

14. Chen H, Hardacre JM, Uzar A et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187(1): 88–92.

15. Lang H, Oldhafer KJ, Weimann A et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997; 225(4): 347–354.

16. Frilling A, Rogiers X, Malago M et al. Liver transplantation in patients with liver metastases of neuroendocrine tumors. Transplant Proc 1998; 30(7): 3298–3300.

17. Le Treut YP, Delpero JR, Dousset B et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997; 225(4): 355–364.

18. Spiliotis JD, Datsis AC, Michalopoulos NV et al. Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. Langebecks Arch Surg 2007; 392(1): 55–60.

19. Date RS, Siriwardena AK. Radiofrequency ablation of the pancreas. II: Intra-operative ablation of non-resectable pancreatic cancer. A description of technique and initial outcome. JOP 2005; 6(6): 588–592.

20. Varshney S, Sewkani A, Sharma S et al. Radiofrequency ablation of unresectable pancreatic carcinoma: feasibility, efficacy and safety. JOP 2006; 7(1): 74–78.

21. Hlavsa J, Kala Z, Válek V et al. Radiofrequency ablation (RFA) of pancreatic tumors. Rozhl Chir 2008; 87(9): 462–466.

22. Matsui Y, Nakagawa A, Kamiyama Y et al. Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas 2000; 20(1): 14–20.

23. Tang Z, Wu YL, Fang HQ et al. Treatment of unresectable pancreatic carcinoma by radiofrequency ablation with ‘cool-tip needle’: report of 18 cases. Zhonghua Yi Xue Za Zhi 2008; 88(6): 391–394.

24. Girelli R, Frigerio I, Salvia R et al. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 2010; 97(2): 220–225.

25. Limmer S, Huppert PE, Juette V et al. Radiofrequency ablation of solitary pancreatic insulinoma in a patient with episodes of severe hypoglycemia. Eur J Gastroenterol Hepatol 2009; 21(9): 1097–1101.

26. Date RS, McMahon RF, Siriwardena AK. Radiofrequency ablation of the pancreas. I: definition of optimal thermal kinetic parameters and the effect of simulated portal venous circulation in an ex-vivo porcine model. JOP 2005; 6(6): 581–587.

27. Solcia E, Kloppel G, Sobin LH et al. Histologic typing of endocrine tumours. WHO International Histological Classification of Tumours. Heidelberg: Springer Verlag 2000.

28. Pederzoli P, Falconi M, Bonora A et al. Cytoreductive surgery in advanced endocrine tumours of the pancreas. Ital J Gastroenterol Hepatol 1999; 31 (Suppl 2): S207–S212.

29. Myers RS, Hammond WG, Ketcham AS. Cryosurgery of primate pancreas. Cancer 1970; 25(2): 411–414.

30. Patiutko I, Barkanov AI, Kholikov TK et al. The combined treatment of locally disseminated pancreatic cancer using cryosurgery. Vopr Onkol 1991; 37(6): 695–700.

31. Penka I, Kaplan Z, Sefr R et al. Use of radiofrequency ablation in the treatment of malignant liver lesions. Hepatogastroenterology 2008; 55(82–83): 562–567.

32. Simon CJ, Dupuy DE. Current role of image-guided ablative therapies in lung cancer. Expert Rev Anticancer Ther 2005; 5(4): 657–666.

33. Suh RD, Wallace AB, Sheehan RE et al. Unresectable pulmonary malignancies: CT guided percutaneous radiofrequency ablation – preliminary results. Radiology 2003; 229(3): 821–829.

34. Noguchi M. Minimally invasive surgery for small breast cancer. J Surg Oncol 2003; 84(2): 94–101.

35. Singletary ES. Feasibility of radiofrequency ablation for primary breast cancer. Breast Cancer 2003; 10(1): 4–9.

36. Boss A, Clasen S, Kuczyk M et al. Magnetic resonance – guided percutaneous radiofrequency ablation of renal cell carcinoma: a pilot clinical study. Invest Radiol 2005; 40(9): 583–590.

37. Wood BJ, Abraham J, Hvizda JL et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003; 97(3): 554–560.

38. Milićević M, Bulajić P, Zuvela M et al. Elective resection of the spleen – overview of resection technics and description of a new technic based on radiofrequency coagulation and dessication. Acta Chir Iugosl 2002; 49(3): 19–24.

39. Shariat SF, Raptidis G, Masotoschi M et al. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate 2005; 65(3): 260–267.

40. Martel J, Bueno A, Ortiz E. Percutaneous radiofrequency treatment of osteoid osteoma using cool-tip electrodes. Eur J Radiol 2005; 56(3): 403–408.

41. Ganaadha S, Wulf S, Morris DL. Safety and efficacy of radiofrequency ablation of brain: a potentially minimally invasive treatment for brain tumors. Minim Invasive Neurosurg 2004; 47(6): 325–328.

42. Chiou YY, Hwang JI, Chou YH et al. Percutaneous ultrasound guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci 2005; 21(7): 304–309.

43. Hadjicostas P, Malakounides N, Varianos C et al. Radiofrequency ablation in pancreatic cancer. HPB 2006; 8(1): 61–64.